Search

Polihexanide

[L53003] It was initially approved in August of 2024, and is the first and only approved therapy to treat patients with _Acanthamoeba_ keratitis. [L53143] … [A1351,A273908] Polihexanide is approved in Europe under the name Akantior for the treatment of _Acanthamoeba_ keratitis, an ocular infection caused by the _Acanthamoeba_ parasite.

Aluminium phosphate

Sinapultide

Surfactant replacement therapy has been commonly used to prevent and treat RDS in these newborns and is now a standard of care. … [L2504] Windtree is currently developing aerosolized KL4 surfactant to treat RDS in premature infants, and thereafter, to potentially address a range of indications in neonatal, pediatric and adult

Mavacamten

[A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471] … It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans.

Brincidofovir

[L34470] As smallpox has been eradicated, the efficacy of Tembexa was assessed in animals infected with viruses closely related to variola. … Brincidofovir, developed by Chimerix under the brand name Tembexa, was approved by the FDA for the treatment of smallpox infection in June 2021.

L-Acetylleucine

DL-) form has been available in France since 1957 for the treatment of vertigo. … [A264439] Observational studies in patients with Niemann-Pick disease type C (NPC) suggested a beneficial symptomatic as well as neuroprotective disease-modifying effect of the DL-form of N-acetylleucine

Imgatuzumab

Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With

Telisotuzumab vedotin

[L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment … Telisotuzumab vedotin is an antibody-drug conjugate comprising [telisotuzumab], a c-Met-directed humanized IgG1κ monoclonal antibody, conjugated to monomethyl auristatin E (MMAE), a small molecule microtubule-disrupting

Mumps virus strain B level jeryl lynn live antigen

It is an active immunization against mumps, which is a common childhood disease.

Fidaxomicin

[A190492] Later that year in December, the drug was also approved by the European Medicine Agency.[A190492] In June 2012, fidaxomicin was also granted approval by Health Canada. … [A190501] Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug.